Background-Cell therapy with bone marrow-derived mononuclear cells (BMCs) can improve recovery of cardiac function after ischemia; however, the molecular mechanisms are not yet fully understood. MicroRNAs (miRNAs) are key regulators of gene expression and modulate the pathophysiology of cardiovascular diseases. Methods and Results-We demonstrated that intramyocardial delivery of BMCs in infarcted mice regulates the expression of cardiac miRNAs and significantly downregulates the proapoptotic miR-34a. In vitro studies confirmed that the supernatant of BMC inhibited the expression of H 2 O 2 -induced miR-34a and cardiomyocytes apoptosis. These effects were blocked by neutralizing antibodies directed against insulin-like growth factor-1 (IGF-1). Indeed, IGF-1 significantly inhibited H 2 O 2 -induced miR-34a expression, and miR-34a overexpression abolished the antiapoptotic effect of IGF-1. Likewise, inhibition of IGF-1 signaling in vivo abolished the BMC-mediated inhibition of miR-34 expression and the protective effect on cardiac function and increased apoptosis and cardiac fibrosis. IGF-1 specifically blocked the expression of the precursor and the mature miR-34a, but did not interfere with the transcription of the primary miR-34a demonstrating that IGF-1 blocks the processing of miR-34a.
C ell-based therapy is a promising option to treat cardiovascular diseases. Bone marrow-derived mononuclear cells (BMCs) improved the recovery after ischemia in various experimental studies and significantly, although modestly, improved cardiac function in patients after acute myocardial infarction (AMI). [1] [2] [3] Multiple mechanisms have been proposed to mediate the therapeutic benefits of BMC therapy, including cell transdifferentiation, cell fusion, and the release of paracrine growth factors and cytokines. 4 In fact, various cytokines and growth factors from transplanted progenitor cells have been shown to elicit positive effects by influencing cardiomyocyte survival, angiogenesis, and the recruitment of endogenous stem cells. 5, 6 Moreover, a recent study suggests that c-kitϩ bone marrow-derived cells activate endogenous regeneration. 7 Clinical Perspective on p 1773 miRNAs are small noncoding RNAs that negatively modulate gene expression by inhibiting protein translation or inducing degradation of the targeted mRNA. 8 miRNAs play an important role in biological processes during development, tissue homeostasis, and disease. 9 -11 Several miRNAs are regulated after the induction of myocardial infarction (MI) and control neovascularization and fibrosis. [12] [13] [14] For example, the increased expression of miR-21 and the downregulation of the miR-29 family members have been associated with cardiac fibrosis, 13, 14 whereas miR-92a and miR-126 regulate neovascularization after cardiac ischemia. 12, 15 Here, we show that administration of BMC in mice after AMI regulates cardiac miRNAs. BMC administration reduced the expression of the profibrotic miR-21 and the proapoptotic miR-34a. We further show that insulin-like growth factor (IGF-1), which is secreted from BMCs, inhibits miR-34a processing and blocks apoptosis of cardiomyocytes in vitro and in vivo. and did not pool cells from individual donors. Cardiomyocytes were isolated from hearts of neonatal rats by the use of collagenase digestion. BMCs were cultured for 24 hours at 37°C in serum-free DMEM in 6-well plates (5ϫ10 6 cells in 2 mL per well) to obtain conditioned supernatants.
RNA Isolation and Quantification
Total RNA was isolated by using the miRNeasy kit (Qiagen, Hilden, Germany). Real-time polymerase chain reaction was performed for measurement of the expression levels of primary, precursor, and mature miRNAs. For detection of mature miRNAs and pri-miRNAs, TaqMan MicroRNA assay kits (Applied Biosystems, Carlsbad, CA) were used in accordance with the manufacturer's protocol. For measurement of the premiRNAs, SYBR green was used. The primer sequences used were previously described. 16 miRNA levels were normalized with RNU6 (human) and snoRNA202 (mouse) expression and mRNA levels with RPLP0.
Transfection and Fluorescence-Activated Cell Sorter Analysis
Transfection of cardiomyocytes with precursor miR (premiR) constructs (from Ambion, Carlsbad, CA) was performed with the use of HiPerfect reagent (Qiagen, Hilden, Germany).
Apoptosis was quantified after incubation of cardiomyocytes with BMC supernatants, H 2 O 2 , with or without neutralizing antibody against IGF-1 (ab9572) or hepatocyte growth factor (ab10678) (both Abcam, Cambridge, United Kingdom) by using Annexin V and 7-AAD staining and flow cytometry analysis by using a CantoII (BD Biosciences, San Jose, CA). Annexin V-positive/7-AAD-negative cell populations were considered apoptotic.
Myocardial Infarction Model
AMI was induced in male nu/nu mice (8 -10 weeks; Charles River, Sulzfeld, Germany) by permanent ligation of the left anterior coronary artery under mechanical ventilation and anesthesia with isoflurane and analgesia with bupivacaine (1 mg/kg, 0.25% bupivacaine 1-3 drops on the incision area) and carprofen (5 mg/kg SC) perioperatively and every 24 hours for 3 days postoperatively. A total of 1 million BMCs were resolved in 50 L PBS and injected intramuscularly into 4 regions in the border zone distal to the ligation of the coronary artery immediately after induction of the MI.
Administration of JB-1, a Peptide IGF-1 Receptor Antagonist
An incision was made in the midscapular region under sterile conditions, and an osmotic minipump (DURECT Corporation, Cupertino, CA) containing either JB-1 (BACHEM, San Carlos, CA) dissolved in PBS or vehicle only was implanted. The delivery rate was 1 mg/kg body weight per day for 7 days as previously described. 17
Administration of Human IGF-1 Recombinant Protein in Vivo
Human recombinant IGF-1 protein (PeproTech, London, United Kingdom) 10 g were resolved in 50 L PBS and injected intramuscularly into 4 regions in the border zone distal to the ligation of the coronary artery immediately after induction of the MI.
IGF1 siRNA Transfection of Human Bone Marrow Cells
IGF1 small interfering RNA (siRNA) and control siRNA were purchased from Sigma-Aldrich (Deisenhofen, Germany). A Nucleofector Device (Amaxa, Gaithersburg, MD) was used to deliver siRNA. In brief, 5 million BMCs were resuspended in 100 L Nucleofector solution. Then, 300 nmol/L of each siRNA was added to the cell suspension. The cells were electroporated with the Amaxa Nucleofector Device. After electroporation, the cells were transferred to regular culture medium and were incubated for 48 hours. After 48 hours, a total of 1 million BMCs were resolved in 50 L PBS and injected intramuscularly into 4 regions in the border zone distal to the ligation of the coronary artery immediately after induction of the MI.
Echocardiography
Echocardiography was performed with high-resolution echocardiography (Vevo770 small animal microultrasound system, VisualSonics, Toronto, Canada). Wall motion score index (WMSI) was analyzed by use of the 16-segment model based on 3-short axis views (4 apical, 6 middle, and 6 basal), with wall motion scored 1 for normal, 2 for hypokinetic, 3 for akinetic, 4 for dyskinetic, 5 for aneurysmal, according to the guidelines of the American Society of Echocardiography. WMSI was calculated as the ratio of the sum of wall motion scores over the total segments scored. 18
Histology
Hearts were perfused with PBS by left ventricular cannulation, immersed in Roti-Histofix (Carl Roth, Karlsruhe, Germany) and then embedded in paraffin. Four-micrometer paraffin sections were cut with a cryotome, and infarct size was measured in 4 sections that were obtained from each heart (distance between sections Ϸ200 m). Infarct size was calculated as previously described. 19 For apoptosis analysis, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling was performed according to the manufacturer's protocol (In Situ Cell Death Detection Kit, Roche Diagnostics, Mannheim, Germany).
MiR-34a Promoter-Luciferase Assay
The miR-34a expression vector was kindly provided by Prof Joshua T. Mendell. 20 For measuring luciferase activity, rat neonatal cardiomyocytes were grown in 12-well plates. Luciferase plasmid (0.2 g) was cotransfected with 0.01 g pGL4 Renilla plasmid (Promega, Madison, WI) as control for the transfection efficiency with the use of Effectene Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The activity of Luciferase and Renilla was assessed with the Dual-Luciferase Reporter Assay System (Promega).
Statistical Analysis
For 2 groups, we used 2-sample t test with equal/unequal variance version depending on variance ratio test. For 3 or more groups, Levene tests were performed to assess variance homogeneity. Standard 1-way ANOVA followed with Tukey-Kramer multiple comparison procedures were performed with homogeneous variances, and the Welch ANOVA followed by Dunnett T3 test was performed with heterogeneous variances. For comparisons of means between groups at different times (3, 5, and 7 days), linear regression with group, time and group*time interaction were performed. All results are presented as mean valueϮstandard error. A final value of PϽ0.05 was considered significant. All statistical analyses were performed with SPSS for Windows 19.0 (SPSS, Inc., Chicago, IL).
Results

BMC Administration Regulates Cardiac miRNAs
To determine whether BMCs regulate miRNA expression in infarcted hearts, we injected human BMCs in infarcted hearts of nude mice and determined the expression of miRNAs. BMC administration improved cardiac function after 7 days ( Figure 1A ). In accordance with previous studies, 12-14 the induction of AMI in PBS-treated control mice increased the expression of miR-21 and miR-92a, whereas miR-29 levels were downregulated ( Figure 1B , online-only Data Supplement Figures IA, IB, and IIA). BMC treatment moderately, but not significantly, reduced the expression of the profibrotic miR-21 in the infarct border zone ( Figure 1B ). Interestingly, BMC administration induced a 1.7-fold (day 3), albeit non-significant upregulation of miR-20a, which is known to augment cellular proliferation by targeting the E2F family of transcription factors and the cell cycle inhibitor p21 [21] [22] [23] ( Figure 1C , online-only Data Supplement Figure IIB ). Furthermore, BMC treatment abolished the AMI-induced upregulation of miR-34a ( Figure 1D , online-only Data Supplement Figure IIC ), which is known to increase apoptosis of tumor cells 24, 25 and inhibits angiogenesis in vitro. 26 In contrast, the expression of miR-92a and miR-29b were not affected by BMC therapy (online-only Data Supplement Figure IA and IB). Together, BMC administration modulates the expression of several miRs, which regulate fibrosis, proliferation, and apoptosis. Because the expression of miR-34a was most efficiently suppressed by BMC treatment in vivo, we further elucidated the regulation and function of miR-34a.
BMC Supernatants Inhibit Cardiac Myocyte miR-34a Expression and Apoptosis in Vitro
To determine whether BMC may inhibit miR-34a expression in a paracrine manner, we induced apoptosis by hydrogen peroxide (H 2 O 2 ) in neonatal rat cardiomyocytes and evalu-ated the effect of conditioned medium derived from cultured BMC. H 2 O 2 increased the expression of miR-34a in a timeand dose-dependent manner with maximal effects seen at 200 mol/L after 12 hours (Figure 2A , data not shown). BMC supernatants significantly suppressed the H 2 O 2 -induced upregulation of miR-34a and reduced cardiomyocyte apoptosis ( Figure 2B and 2C). To identify the factor(s) that mediate the protective effect of BMC supernatants, the antiapoptotic cytokines IGF-1 and hepatocyte growth factor, which are known to be released by BMC, 27 were blocked by neutralizing antibodies. The antiapoptotic effect of BMC supernatants on miR-34a expression and apoptosis was significantly reversed by a neutralizing antibody directed against IGF-1, whereas anti-hepatocyte growth factor antibodies had no effect ( Figure 2B and 2C) . Indeed, recombinant IGF-1 protein inhibited H 2 O 2 -induced miR-34a expression (28.1Ϯ5.7% inhibition, PϽ0.05). In addition, miR-34a overexpression significantly augmented baseline as well as H 2 O 2 -induced apoptosis in cardiomyocytes in comparison with control transfection, and miR-34a overexpression abrogated the antiapoptotic effect of IGF-1 ( Figure 2D ). Furthermore, the phosphatidylinositol 3-kinase inhibitor LY294002 signifi- cantly reversed the inhibitory effect of IGF-1 on H 2 O 2induced miR-34a expression (46.7Ϯ13.0%, PϽ0.05), suggesting that IGF-1 mediates its effects predominantly via the Akt/phosphatidylinositol 3-kinase pathway. These data suggest that IGF-1, which is secreted by BMC, inhibits H 2 O 2induced miR-34 expression and blocks cardiomyocyte apoptosis in vitro.
IGF-1 Mediates the Protective Effect of BMC in Vivo
To investigate whether BMC-secreted IGF-1 is required for the cardioprotective responses of BMC treatment, we inhibited IGF-1 signaling in vivo by systemically applying the IGF-1 receptor antagonist JB1, which competes with IGF-1 to inhibit autophosphorylation of the receptor. 28 The decrease in WMSI (Ϫ0.39Ϯ0.18) was reduced by JB1-treatment (Ϫ0.19Ϯ0.21) ( Figure 3A and 3B ). Furthermore, inhibition of IGF-1 signaling reversed the BMC-mediated inhibition of apoptosis ( Figure 3C ) and accelerated cardiac fibrosis in BMC-treated mice ( Figure 3D ). Consistently, in situ hybridization revealed that JB-1 treatment augmented miR-34a expression in the border zone of BMC-treated mice, and PBS-treated mice in comparison with BMC-treated mice receiving PBS, as well (online-only Data Supplement Figure III) .
Together, these data demonstrate that inhibition of IGF-1 signaling reversed the effect of BMC therapy on cardiac apoptosis and miR-34a expression in mice after AMI. 
BMC-Derived IGF-1 Mediates the Upregulation of Endogenous IGF-1 in Vivo
Next, we investigated whether BMCs upregulate the expression of IGF-1 and thereby inhibit miR-34a expression in infarcted hearts. Consistent with a previous study, 29 administration of BMCs significantly increased the expression of IGF-1 mRNA in the infarcted hearts in comparison with the PBS group ( Figure 4A) . To identify the source of increased IGF-1 expression in vivo, we measured the expression of BMC-derived human versus host-derived mouse IGF-1 mRNA by using human-and mouse-specific primers. The human IGF-1 originating from human BMC peaked at day 1 and subsequently declined within 3 days. In contrast, hostderived mouse IGF-1 mRNA levels were profoundly increased at day 3 and remained elevated up to 7 days ( Figure  4B ). To further investigate the possibility that BMC-derived IGF-1 might mediate the induction of endogenous IGF-1, we injected human recombinant IGF-1 protein in infarcted hearts of nude mice and determined the effect on host-derived mouse IGF-1 and miR-34a expression. Administration of recombinant IGF-1 protein significantly increased mouse IGF-1 expression and decreased miR-34a expression ( Figure  4C and 4D) . To further elucidate the causal role of BMCderived IGF-1 in regulating miR-34a expression, we transfected human BMC with siRNA directed against IGF-1. siRNA directed against IGF-1 significantly suppressed IGF-1 expression in BMCs by Ϸ65% in comparison with control siRNA ( Figure 4E ). Inhibition of IGF-1 by siRNA in transplanted BMC significantly increased miR-34a expression in comparison with the control BMC treated hearts demonstrating that BMC-derived IGF-1 is required to reduce miR-34a in the infarcted heart ( Figure 4F ).
Regulation of miR-34a Expression and Processing
The generation of mature miRs is regulated by the expression of the primary miRNA (pri-miR) and is additionally controlled at various steps of the miR biosynthesis pathways. Pri-miRs are cropped into a hairpin structure leading to the formation of the premiRs which are subsequently exported from the nucleus and processed into the Ϸ22-nucleotide mature miR. 30 MiR-34a is an intergenic miR that is controlled by its own promoter. 20 To determine by which mechanism IGF-1 controls miR-34 synthesis, luciferase reporter constructs encoding the miR-34 promoter were used. However, IGF-1 did not significantly affect basal and H 2 O 2 -induced reporter gene activity ( Figure 5A) suggesting that IGF-1 interferes with miR-34 processing. Consistent with this model, IGF-1 only slightly reduced the expression of the pri-miR-34 in H 2 O 2 -treated cardiomyocytes ( Figure 5B) , whereas the levels of the premiR-34 were significantly reduced by IGF-1 to 48.4Ϯ11.4% ( Figure 5C ). To demonstrate whether BMCs also affect miR-34 expression in vivo by a similar mechanism, we determined the expression of the pri-miR-34 and premiR-34 in vivo. Indeed, BMC administration did not affect the expression of the pri-miR-34, whereas the premiR-34 levels were significantly reduced in infarcted hearts ( Figure 5D and 5E).
Discussion
The data of the present study demonstrate that BMC administration regulates the expression of miRs in the infarcted hearts in mice. In particular, the expression of the proapoptotic miR-34a was significantly reduced in the infarct border zone in mice after BMC therapy. The effects of BMC on cardiac miR expression are probably attributable to the release of paracrine factors, because BMC supernatants block H 2 O 2 -induced expression of miR-34a in cardiomyocytes in vitro. BMCs secrete various factors, which are known to provide protective effects on cardiomyocytes, including various antiapoptotic and anti-inflammatory cytokines. 31, 32 Among the factors tested, we showed that inhibition of the antiapoptotic cytokine IGF-1 by using neutralizing antibodies reduced the antiapoptotic effects of BMC supernatants on cardiac apoptosis and miR-34a expression in vitro. In addition, systemic inhibition of IGF-1 functions by antagonistic peptides reversed the beneficial effect of BMC on cardiac function and apoptosis in vivo. IGF-1 is well known for its cardioprotective effects under stress conditions. 33-36 IGF-1 overexpression or local myocardial delivery of IGF-1 improved myocyte survival and protected against ventricular dilatation after infarction. 37,38 IGF-1 additionally stimulates endogenous regeneration and increased the number and differentiation of coinjected cardiac stem cells. 39 BMCs secrete IGF-1 in vitro, 27 and administration of BMCs increased the expression of IGF-1 mRNA in infarcted hearts ( Figure 4A and 4B ). Of note, consistent with previous studies, 29 transplanted BMC directly provided IGF-1 as demonstrated by the increased expression of human IGF-1 mRNA, but also induced a longer-term expression of host tissue-derived murine IGF-1 mRNA, suggesting that BMC therapy directly and indirectly stimulated IGF-1 expression in the infarcted tissue. Together these data disclose a crucial function of IGF-1 in mediating the antiapoptotic and cardioprotective effects of BMC. However, given the reported pleiotropic effects of BMC, it is likely that additional mechanisms may contribute to the observed beneficial effects of BMC on angiogenesis and long-term remodeling. Indeed, blocking IGF-1 resulted in a higher mortality in the mice after AMI without BMC transplantation (38.4% survival) in comparison with JB-1-treated mice, which additionally receive BMC transplantation (70.5% survival) suggesting that BMCs even show an additional protective effect under conditions when IGF-1 signaling is blocked (online-only Data Supplement Figure IV) .
IGF-1 improves cell survival by activating prosurvival kinases such as Akt. 40 The present study now provides additional insights into the mechanism underlying the antiapoptotic activity of IGF-1. IGF-1 inhibits the stress-induced expression of miR-34 in a phosphatidylinositol 3-kinasedependent manner. These findings are consistent with a recent study showing that phosphatidylinositol 3-kinase inhibition is associated with increased levels of miR-34. 41 MiR-34 was shown to induce apoptosis in various cell types and targets protective proteins such as SIRT1. 24 Interestingly, the overexpression of locally acting IGF-1 increased SIRT1 expression and activity, thereby preventing hypertrophy and oxidative stress in the heart. 42 In addition, miR-34 regulates p53 activity and controls cell cycle progression and senescence. 25 Therefore, one may speculate that inhibition of miR-34 processing may contribute to the well-established protective effects of IGF-1 under stress conditions.
Our data suggest that the inhibition of miR-34a expression is preferentially controlled by an inhibition of miR-34a processing. Although the expression of the pri-miR-34a is induced by H 2 O 2 in a p53-dependent manner (online-only Data Supplement Figure V) , IGF-1 did not reduce H 2 O 2induced induction of the pri-miR-34a and activation of the miR-34a promoter in luciferase assays in vitro. Likewise, BMC therapy did not reduce pri-miR-34a expression suggesting that both BMC and IGF-1 inhibit miR-34a processing. Several studies suggest a crucial role of miR metabolism by various mechanisms involving protein-protein and protein-RNA interactions. 16, 43, 44 Therefore, further studies should elucidate the signaling pathways mediating the inhibitory effects of IGF-1 on miR-34 processing.
In summary, the present study demonstrates that administration of BMCs regulates cardiomyocyte miR-34a expression and apoptosis in a paracrine manner by secreting IGF-1. IGF-1-mediated inhibition of miR-34a may contribute to several of the known cardioprotective functions of IGF-1 ( Figure 6 ). Figure 6 . Proposed mechanisms of the paracrine regulation of cardiac miRNAs by transplanted BMCs. Transplanted BMCs regulate cardiac miRNAs. BMCs release IGF-1, which inhibits the processing of miR-34a, thereby blocking cardiomyocyte apoptosis. IGF-1 indicates insulin-like growth factor-1; BMC, bone marrow-derived mononuclear cell; premiR, precursor miR; pri-miR, primary miRNA. Analysis was performed with 1-way ANOVA followed by Dunnett T3 post hoc analysis. *PϽ0.05 versus without H 2 O 2 ; †PϽ0.05 versus IGF-1 without H 2 O 2 ; ‡PϽ0.05 versus H 2 O 2 (nϭ14, each group). (D) Effect of BMC treatment on pri-miR-34a expression 1 week after myocardial infarction. Pri-miR34a levels were determined by q-PCR. Analysis was performed with 1-way ANOVA followed by Dunnett T3 post hoc analysis (nϭ10 -11, each group). (E) The effect of BMC treatment on premiR-34a expression 1 week after myocardial infarction. PremiR34a levels were determined by q-PCR. The Tukey-Kramer tests followed by 1-way ANOVA were used for comparisons. *PϽ0.05 versus sham; †PϽ0.05 versus PBS (nϭ10 -11, each group). q-PCR indicates quantitative polymerase chain reaction; premiR, precursor miR; pri-miR, primary miRNA; IGF-1, insulin-like growth factor-1; BMC, bone marrow-derived mononuclear cell.
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